Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6.

As an extension of research, we have investigated modification of left-hand side (LHS) of biphenyl analogues containing an acylsulfonamide moiety in the development of potent and selective human beta(3)-adrenergic receptor (AR) agonists. Result of structure-activity relationships (SAR) and cassette-dosing evaluation in dogs showed that the hydroxynorephedrine analogue 16 had an excellent balance of in vitro and in vivo potency with pharmacokinetic profiles. In addition, to facilitate structure-based drug design (SBDD), we also have performed a docking study of biphenyl analogues based on the X-ray structure of the beta(2)-adrenergic receptor.

[1]  C. Cowan,et al.  Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres. , 2002, Journal of medicinal chemistry.

[2]  M. Sakurai,et al.  Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety. , 2008, Journal of medicinal chemistry.

[3]  M. Sakurai,et al.  Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5. , 2009, Journal of medicinal chemistry.

[4]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[5]  Nobuhiro Yamamoto,et al.  Discovery of novel series of benzoic acid derivatives containing biphenyl ether moiety as potent and selective human beta(3)-adrenergic receptor agonists: Part IV. , 2008, Bioorganic & medicinal chemistry letters.

[6]  R. Stevens,et al.  GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function , 2007, Science.

[7]  R. Glen,et al.  Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.

[8]  H. Mukaiyama,et al.  Relationship between stereochemistry and the beta3-adrenoceptor agonistic activity of 4'-hydroxynorephedrine derivative as an agent for treatment of frequent urination and urinary incontinence. , 2003, Journal of medicinal chemistry.

[9]  A. Mathur,et al.  Carboxyl-promoted enhancement of selectivity for the β3 adrenergic receptor. Negative charge of the sulfonic acid BMS-187413 introduces-β3 binding selectivity , 1997 .

[10]  M. Sakurai,et al.  Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II. , 2008, Journal of medicinal chemistry.

[11]  R. Gregg,et al.  Beta 3 agonists. Part 1: evolution from inception to BMS-194449. , 2001, Bioorganic & medicinal chemistry letters.

[12]  M. Sawa,et al.  Recent developments in the design of orally bioavailable beta3-adrenergic receptor agonists. , 2006, Current medicinal chemistry.

[13]  M. Sennitt,et al.  Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs , 1984, Nature.